Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading CVM News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.31%||72.13||1.0%||$655.07m|
|ARIA||ARIAD Pharmaceuticals, Inc.||0.23%||23.70||16.4%||$416.43m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.42%||135.87||2.5%||$385.05m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.08%||362.95||2.5%||$365.07m|
|CLVS||Clovis Oncology, Inc.||0.64%||56.62||17.9%||$166.73m|
|VRTX||Vertex Pharmaceuticals Incorporated||1.19%||82.52||2.1%||$152.50m|
|SRPT||Sarepta Therapeutics, Inc.||-0.42%||35.98||16.8%||$110.90m|
|ACAD||ACADIA Pharmaceuticals Inc.||3.06%||32.31||18.3%||$110.16m|
|IONS||Ionis Pharmaceuticals, Inc.||1.12%||47.14||8.9%||$110.11m|
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.